Investigating the Potential for Toxicity from Long-Term Use of the Herbal Products, Goldenseal and Milk Thistle

Toxicologic Pathology

Volumn 39, Issue 2, 2011, Pages 398-409

  Dunnick, June K ^a   Singh, Bhanu ^b   Nyska, Abraham ^c   Peckham, John ^c   Kissling, Grace E ^a   Sanders, J Michael ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b DUPONT COMPANY   (United States)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

goldenseal; herbal products; milk thistle

Indexed keywords

BERBERINE; BEROLINE; CANADINE; DNA; DNA TOPOISOMERASE; FLAVONOLIGNAN; HERBACEOUS AGENT; HYDRASTINE; HYDRASTIS EXTRACT; ISOSILYBIN A; ISOSILYBIN B; ISOSILYCHRISTIN; PALMATINE; PLANT EXTRACT; SILIBININ; SILICRISTIN; SILIDIANIN; SILYBIN A; SILYBIN B; SILYBUM MARIANUM EXTRACT; TAXIFOLIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; BREAST TUMOR; CARCINOGENESIS; CARCINOGENICITY; CONTROLLED STUDY; DNA REPAIR; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; HISTOPATHOLOGY; HYDRASTIS; LIVER TUMOR; MALE; MOUSE; NONHUMAN; PLANT ROOT; PRIORITY JOURNAL; RAT; SILYBUM MARIANUM;

ANIMALS; BERBERINE; BODY WEIGHT; CARCINOGENS; FEMALE; FLAVONOLIGNANS; HYDRASTIS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED STRAINS; MILK THISTLE; PLANT PREPARATIONS; PLANT ROOTS; RATS; RATS, INBRED F344; SILYMARIN; TOPOISOMERASE INHIBITORS; TOXICITY TESTS, CHRONIC;

HYDRASTIS CANADENSIS; MUS; RATTUS; RODENTIA; SILYBUM MARIANUM;

EID: 79954549226     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623310394211     Document Type: Article

References (67)

1. Abidi P. Chen W. Kraemer F. B. Li H. Liu J. (2006). The medicinal plant goldenseal is a natural LDL-lowering agent with multiple bioactive components and new action mechanisms. J Lipid Res 47, 2134–147.
2. Abourashed E. A. Khan I. A. (2001). High-performance liquid chromatography determination of hydrastine and berberine in dietary supplements containing goldenseal. J Pharm Sci 90, 817–22.
3. Awang D. (1993). Milk thistle. Can. Pharm. J 126, 403–04, 422.
4. Bailer A. J. Portier C. J. (1988). Effects of treatment-induced mortality and tumor-induced mortality on tests for carcinogenicity in small samples. Biometrics 44, 417–31.
5. Barnes P. M. Bloom B. Nahin R. L. (2008). Complementary and Alternative Medicine Use Among Adults and Children: United States, 2007. National Health Statistics Reports Number 12, December 10, 2008, available from NCCAM web site: http://nccam.nih.gov/news/camstats.htm.
6. Boorman G. A. Eustis S. L. (1986). The pathology working roup as a means for assuring pathology quality in toxicologic studies. In Managing conduct and data quality of toxicologic studies (Whitmire C. Davis CL Bristol DW, Ed., pp. 271–275. Princeton Scientific Publishing, Princeton.
7. Champoux J. J. (2001). DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 70, 369–413.
8. Cohen P. A. (2009). American roulette—Contaminated dietary supplements. N Engl J Med 361, 1523–525.
9. Comelli M. C. Mengs U. Schneider C. Prosdocimi M. (2007). Toward the definition of the mechanism of action of silymarin: Activities related to cellular protection from toxic damage induced by chemotherapy. Integr Cancer Ther 6, 120–29.
10. Cox D. R. (1972). Regression models and life-tables. J R Stat Soc B34, 187–220.
11. Crocenzi F. A. Roma M. G. (2006). Silymarin as a new hepatoprotective agent in experimental cholestasis: new possibilities for an ancient medication. Curr Med Chem 13, 1055–074.
12. Cui W. Gu F. Hu K. Q. (2009). Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice. World J Gastroenterol 15, 1943–950.
13. Davis-Searles P. R. Nakanishi Y. Kim N. C. Graf T. N. Oberlies N. H. Wani M. C. Wall M. E. Agarwal R. Kroll D. J. (2005). Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res 65, 4448–457.
14. Deep G. Singh R. P. Agarwal C. Kroll D. J. Agarwal R. (2006). Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: A comparison of flavanone silibinin with flavanolignan mixture silymarin. Oncogene 25, 1053–069.
15. Detaille D. Sanchez C. Sanz N. Lopez-Novoa J. M. Leverve X. El-Mir M. Y. (2008). Interrelation between the inhibition of glycolytic flux by silibinin and the lowering of mitochondrial ROS production in perifused rat hepatocytes. Life Sci 82, 1070–076.
16. El-Kamary S. S. Shardell M. D. Abdel-Hamid M. Ismail S. El-Ateek M. Metwally M. Mikhail N. Hashem M. Mousa A. Aboul-Fotouh A. El-Kassas M. Esmat G. Strickland G. T. (2009). A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis. Phytomedicine 16, 391–400.
17. El-Serag H. B. Rudolph K. L. (2007). Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557–576.
18. Etheridge A. S. Black S. R. Patel P. R. So J. Mathews J. M. (2007). An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med 73, 731–41.
19. Feng Z. Hu W. Teresky A. K. Hernando E. Cordon-Cardo C. Levine A. J. (2007). Declining p53 function in the aging process: A possible mechanism for the increased tumor incidence in older populations. Proc Natl Acad Sci U S A 104, 16633–638.
20. Fraschini F. Demartini G. Esposti D. (2002). Pharmacology of silymarin. Clin Drug Invest 22, 51–65.
21. Freireich E. J. Gehan E. A. Rall D. P. Schmidt L. H. Skipper H. E. (1966). Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50, 219–44.
22. Fu H. Lin M. Muroya Y. Hata K. Katsumura Y. Yokoya A. Shikazono N. Hatano Y. (2009). Free radical scavenging reactions and antioxidant activities of silybin: mechanistic aspects and pulse radiolytic studies. Free Radic Res 43, 887–97.
23. Gazak R. Walterova D. Kren V. (2007). Silybin and silymarin—New and emerging applications in medicine. Curr Med Chem 14, 315–38.
24. Goldsworthy T. L. Fransson-Steen R. (2002). Quantitation of the cancer process in C57BL/6J, B6C3F1 and C3H/HeJ mice. Toxicol Pathol 30, 97–105.
25. Gospodinov A. Ivanov R. Anachkova B. Russev G. (2003). Nucleotide excision repair rates in rat tissues. Eur J Biochem 270, 1000–005.
26. Greenlee H. Abascal K. Yarnell E. Ladas E. (2007). Clinical applications of Silybum marianum in oncology. Integr Cancer Ther 6, 158–65.
27. Grycova L. Dostal J. Marek R. (2007). Quaternary protoberberine alkaloids. Phytochemistry 68, 150–75.
28. Hamon N. W. (1990). Herbal medicine—Goldenseal. Can Pharm J 123, 508–10.
29. Hardisty J. G. Boorman G. A. (1986). National Toxicology Program pathology quality assurrance procedures. In Managing conduct and data quality of toxicologic studies (Whitmire C. Davis CL Bristol DW Ed., pp. 263–269. Princeton Publishing Company, Princeton, NJ.
30. Haseman J. K. Young E. Eustis S. L. Hailey J. R. (1997). Body weight-tumor incidence correlations in long-term rodent carcinogenicity studies. Toxicol Pathol 25, 256–63.
31. Hoshida Y. Nijman S. M. Kobayashi M. Chan J. A. Brunet J. P. Chiang D. Y. Villanueva A. Newell P. Ikeda K. Hashimoto M. Watanabe G. Gabriel S. Friedman S. L. Kumada H. Llovet J. M. Golub T. R. (2009). Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 69, 7385–392.
32. International Agency for Cancer Research. (2000). Some antiviral and antineoplastic drugs, and other pharmaceutical agents. 76, 175–344.
33. Ittrich C. Deml E. Oesterle D. Kuttler K. Mellert W. Brendler-Schwaab S. Enzmann H. Schladt L. Bannasch P. Haertel T. Monnikes O. Schwarz M. Kopp-Schneider A. (2003). Prevalidation of a rat liver foci bioassay (RLFB) based on results from 1600 rats: A study report. Toxicol Pathol 31, 60–79.
34. Kaleeswaran S. Sriram P. Prabhu D. Mathuram L. N. (2009). Anti- and pro-mutagenic effects of silymarin in the ames bacterial reverse mutation assay. Phytother Res 23, 1378–384.
35. Kettmann V. Kosfalova D. Jantova S. Cernakova M. Drimal J. (2004). In vitro cytotoxicity of berberine against HeLa and L1210 cancer cell lines. Pharmazie 59, 548–51.
36. Kim N. C. Graf T. N. Sparacino C. M. Wani M. C. Wall M. E. (2003). Complete isolation and characterization of silybins and isosilybins from milk thistle (Silybum marianum). Org Biomol Chem 1, 1684-689
37. Kobayashi Y. Yamashita Y. Fujii N. Takaboshi K. Kawakami T. Kawamura M. Mizukami T. Nakano H. (1995). Inhibitors of DNA topoisomerase I and II isolated from the Coptis rhizomes. Planta Med 61, 414–18.
38. Kroll D. J. Shaw H. S. Oberlies N. H. (2007). Milk thistle nomenclature: Why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther 6, 110–19.
39. Kulkarni S. K. Dhir A. (2009). Berberine: A plant alkaloid with therapeutic potential for central nervous system disorders. Phytother Res 24, 317–24.
40. Lee J. I. Narayan M. Barrett J. S. (2007). Analysis and comparison of active constituents in commercial standardized silymarin extracts by liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 845, 95–103.
41. [not in text] Li L. Zeng J. Gao Y. He D. (2010). Targeting silibinin in the antiproliferative pathway. Expert Opin Investig Drugs 19, 243–55.
42. Makhey D. Gatto B. Yu C. Liu A. Liu L. F. LaVoie E. J. (1994). Protoberberine alkaloids and related compounds as dual inhibitors of mammalian topisomerase I and II. Med Chem Res 5, 1–12.
43. Malik M. Nitiss K. C. Enriquez-Rios V. Nitiss J. L. (2006). Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage. Mol Cancer Ther 5, 1405–414.
44. Mazzini S. Bellucci M. C. Mondelli R. (2003). Mode of binding of the cytotoxic alkaloid berberine with the double helix oligonucleotide d(AAGAATTCTT)(2). Bioorg Med Chem 11, 505–14.
45. Meeran S. M. Katiyar S. K. (2008). Cell cycle control as a basis for cancer chemoprevention through dietary agents. Front Biosci 13, 2191–202.
46. Morazzoni P. Montalbetti A. Malandrino S. Pifferi G. (1993). Comparative pharmacokinetics of silipide and silymarin in rats. Eur J Drug Metab Pharmacokinet 18, 289–97.
47. National Institutes of Health (2010). Clinical trials database. http://clinicaltrials.gov/ct2/results?term=milk+thistle
48. Olinski R. Siomek A. Rozalski R. Gackowski D. Foksinski M. Guz J. Dziaman T. Szpila A. Tudek B. (2007). Oxidative damage to DNA and antioxidant status in aging and age-related diseases. Acta Biochim Pol 54, 11–26.
49. Pan J. F. Yu C. Zhu D. Y. Zhang H. Zeng J. F. Jiang S. H. Ren J. Y. (2002). Identification of three sulfate-conjugated metabolites of berberine chloride in healthy volunteers' urine after oral administration. Acta Pharmacol Sin 23, 77–82.
50. Piegorsch W. W. Bailer A. J. (1997). Statistics for Environmental Biology and Toxicology. In (Hall C. A., Ed., Vol. Section 6.3.2. Chapman and Hall, London.
51. Polyak S. J. Morishima C. Lohmann V. Pal S. Lee D. Y. Liu Y. Graf T. N. Oberlies N. H. (2010). Identification of hepatoprotective flavonolignans from silymarin. Proc Natl Acad Sci U S A 107, 5995–999.
52. Portier C. J. Bailer A. J. (1989). Testing for increased carcinogenicity using a survival-adjusted quantal response test. Fundam Appl Toxicol 12, 731–37.
53. Qiu W. Jiang X. H. Liu C. X. Ju Y. Jin J. X. (2009). Effect of berberine on the pharmacokinetics of substrates of CYP3A and P-gp. Phytother Res 11, 1553–558.
54. Ramakrishnan G. Jagan S. Kamaraj S. Anandakumar P. Devaki T. (2009). Silymarin attenuated mast cell recruitment thereby decreased the expressions of matrix metalloproteinases-2 and 9 in rat liver carcinogenesis. Invest New Drugs 27, 233–40.
55. Seeff L. B. Curto T. M. Szabo G. Everson G. T. Bonkovsky H. L. Dienstag J. L. Shiffman M. L. Lindsay K. L. Lok A. S. Di Bisceglie A. M. Lee W. M. Ghany M. G. (2008). Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology 47, 605–12.
56. Shih P. H. Yen G. C. (2007). Differential expressions of antioxidant status in aging rats: the role of transcriptional factor Nrf2 and MAPK signaling pathway. Biogerontology 8, 71–80.
57. Singh R. P. Tyagi A. K. Zhao J. Agarwal R. (2002). Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen-activated protein kinases and induction of apoptosis. Carcinogenesis 23, 499–510.
58. Stout M. D. Kissling G. E. Suarez F. A. Malarkey D. E. Herbert R. A. Bucher J. R. (2008). Influence of Helicobacter hepaticus infection on the chronic toxicity and carcinogenicity of triethanolamine in B6C3F1 mice. Toxicol Pathol 36, 783–94.
59. Sun Y. Xun K. Wang Y. Chen X. (2009). A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs. Anticancer Drugs 20, 757–69.
60. Takahashi M. Dinse G. E. Foley J. F. Hardisty J. F. Maronpot R. R. (2002). Comparative prevalence, multiplicity, and progression of spontaneous and vinyl carbamate-induced liver lesions in five strains of male mice. Toxicol Pathol 30, 599–605.
61. Tarone R. E. (1975). Tests for trend in life table analysis. Biometrika 62, 679–82.
62. U. S. Food and Drug Administration. (1994). Dietary Supplement Health and Education Act of 1994. Public Law 103-417, 103rd Congress. http://www.fda.gov/opacom/laws/dshea.html.
63. U. S. National Institutes of Health. (2009). ClinicalTrials.gov. http://clinicaltrials.gov/ct2/home.
64. Wen Z. Dumas T. E. Schrieber S. J. Hawke R. L. Fried M. W. Smith P. C. (2008). Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos 36, 65–72.
65. World Health Organization (accessed 2010). Traditional Medicine. http://www.who.int/mediacentre/factsheets/fs134/en/.
66. Wu Y. F. Fu S. L. Kao C. H. Yang C. W. Lin C. H. Hsu M. T. Tsai T. F. (2008). Chemopreventive effect of silymarin on liver pathology in HBV X protein transgenic mice. Cancer Res 68, 2033–042.
67. Zuo F. Nakamura N. Akao T. Hattori M. (2006). Pharmacokinetics of berberine and its main metabolites in conventional and pseudo germ-free rats determined by liquid chromatography/ion trap mass spectrometry. Drug Metab Dispos 34, 2064–072.